Compass Therapeutics, Inc. (CMPX)
Automate Your Wheel Strategy on CMPX
With Tiblio's Option Bot, you can configure your own wheel strategy including CMPX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CMPX
- Rev/Share 0.0268
- Book/Share 1.0059
- PB 2.3661
- Debt/Equity 0.0497
- CurrentRatio 31.8385
- ROIC -0.4
- MktCap 329113540.0
- FreeCF/Share -0.3496
- PFCF -6.8423
- PE -6.8565
- Debt/Assets 0.0461
- DivYield 0
- ROE -0.3237
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CMPX | Leerink Partners | Market Perform | Outperform | -- | $6 | April 2, 2025 |
| Initiation | CMPX | Guggenheim | -- | Buy | -- | $12 | Feb. 24, 2025 |
| Initiation | CMPX | Piper Sandler | -- | Overweight | -- | $12 | Feb. 19, 2025 |
| Initiation | CMPX | D. Boral Capital | -- | Buy | -- | $32 | Dec. 23, 2024 |
| Upgrade | CMPX | Ladenburg Thalmann | Neutral | Buy | -- | $5 | Sept. 16, 2024 |
News
Compass Therapeutics to Participate in Upcoming May Investor Events
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C.
Read More
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.
Read More
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.
Read More
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Read More
About Compass Therapeutics, Inc. (CMPX)
- IPO Date 2021-04-05
- Website https://www.compasstherapeutics.com
- Industry Biotechnology
- CEO Dr. Thomas J. Schuetz M.D., Ph.D.
- Employees 35